Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

EQB secures final approval for PC Financial acquisition and prepares for closing to bring competitive change to Canadian banking

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Frontier Airlines Reports First Quarter 2026 Financial Results

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

IPG Photonics Announces First Quarter 2026 Financial Results

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Southwest Gas Holdings, Inc. Reports First Quarter 2026 Financial Results, Affirms Full-Year 2026 and Long-Term Guidance

CG Oncology to Present at Upcoming Investor Conferences in May

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

Septerna to Present at Bank of America Securities Health Care Conference

Momentus Publishes Letter to Shareholders Highlighting Progress

Portillo’s Inc. Announces First Quarter 2026 Financial Results

GraniteShares Announces Monthly Distributions for its Autocallable ETFs: ANV and TLA

red violet to Present at the 26th Annual B. Riley Securities Investor Conference

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

Randstad USA and FEI Form Alliance to Address Financial Technology Transformation and Talent Needs

Oracle Supports Africa Clinical Research Network (ACRN) to Advance a New Era of Clinical Research, Launches First Trial

NanoXplore Launches xGnP™ D500-HP, High-Purity Graphene to Replace Conventional Conductive Additives